Elad Sharon: The hottest new ICI BOTENSILIMAB in Kidney Cancer
Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Michael Serzan, Genitourinary Medical Oncologist from Dana-Farber Cancer Institute, on X adding:
“I think this effort is incredible! I cannot recall another trial of an IO combination in development that was directly compared to the competing combination in the same class, sponsored by the company…. This is not a small statement. I am impressed with Agenus Inc.”
Quoting Michael Serzan’s post:
“Interested in learning about the hottest new ICI BOTENSILIMAB in Kidney Cancer? Follow the thread below and check out TIP Poster ASCO GU24 Saturday 01/27/24 7-8am, 1130-1pm .
ARCITECT
RP2 at 13 sites.
ALL Risk ccRCC, no prior Tx.
ArmA: BOT/BAL (80) ArmB: NIVO/IPI (40)
BACKGROUND
NIVO/IPI has robust landmark PFS, OS, and TFS CM214 what mediates resistance to anti-PD1 in RCC? Data from Signoretti Lab shows that Treg in the tumor microenvironment are critical to PD1 resistance.
Can we target Treg in the TME? BOTENSILIMAB is a novel Fc-enhanced CLTA inhibitor that has shown efficacy in tumors due to novel features:
- Treg depletion.
- Enhance T cell priming and antigenicity.
- Decrease complement-mediated toxicity.
Recent Data across multiple tumors
- MSS colon cancer, NEST1.
- Refractory Sarcoma, ESMO23.
- Ongoing trial in Lung Cancer, Mark Awad.
Come check out TIP poster at ASCO GU24 Saturday 01/27/24 7-8am, 1130-1pm to learn more about:
- novel dosing strategy.
- ICI tox mgmt.
- IIT development/ mentorship.
BONUS we can exchange favorite Peleton rides and coffee recommendations.
Grateful for the greatest mentors on the planet Toni Choueiri, Bradley McGregor, Dr. Atkins and ARCITECT investigators for their continual support developing this INVESTIGATOR INITIATED TRIAL opening at 13 HCRN sites Science is HARD WORK but teamwork makes the dream work.”
Source: Elad Sharon/X and Michael Serzan/X